We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma (BENTLY)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00959686
First Posted: August 17, 2009
Last Update Posted: February 12, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Mundipharma Pte Ltd.
Information provided by (Responsible Party):
French Innovative Leukemia Organisation
  Purpose
A Phase II clinical study to determine the efficacy of single agent Bendamustine for T cell lymphoma "BENTLY".

Condition Intervention Phase
T-cell Lymphoma Drug: Bendamustine Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma. A Phase II Multicenter Study "BENTLY"

Resource links provided by NLM:


Further study details as provided by French Innovative Leukemia Organisation:

Primary Outcome Measures:
  • Determine the overall response rate (ORR) (CR+CRu+PR) [ Time Frame: 36 months follow-up ]

Secondary Outcome Measures:
  • Evaluation of the tolerance and Safety of bendamustine in this subset of patients [ Time Frame: 36 months follow-up ]
  • Determination of the progression free survival (PFS), time to treatment failure (TTF), time to progression (TTP), overall survival (OS) and the duration of response. [ Time Frame: 36 months follow-up ]

Estimated Enrollment: 45
Study Start Date: September 2009
Study Completion Date: February 2013
Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Bendamustine
Bendamustine at the dose of 120 mg/m2 IV over 60 minutes on days 1 and 2 every 21 days for 6 cycles
Drug: Bendamustine
Bendamustine at the dose of 120 mg/m2 IV over 60 minutes on days 1 and 2 every 21 days for 6 cycles
Other Name: Ribomustin®

Detailed Description:
The primary objective of this study is to define the activity of Bendamustine for the treatment of T cells lymphomas. The activity of Bendamustine is determined by the response rate (RR) to the treatment within 22 days after intravenous infusion which enables to get a confidence interval of 95 % for the probability of an overall response rate (ORR).
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients aged more than 18 years.
  • Refractory or relapsed peripheral T-cell NHL (PTCL)
  • Cutaneous T cell lymphoma (CTCL) in relapse or refractory to topical therapy
  • ECOG score less than 2
  • No major organ dysfunction unrelated to lymphoma.

Exclusion Criteria:

  • Pregnant or breast feeding women
  • ECOG score > 2
  • Estimate survival time < 3 months
  • Active infection or severe organ dysfunction or psychiatric condition that unable patients to receive chemotherapy
  • Creatinine clearance < 10 ml/min or severe hepatic dysfunction not related to lymphoma.
  • Previous chemotherapy/immunotherapy within 3 weeks before study entry
  • Known seropositive for or active viral infection HIV, EBV, HCV
  • CNS lymphoma
  • T-cell Leukemia lymphoma associated with HTLV1
  • Sezary syndrome
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00959686


Locations
France
Dr Gandhi DAMAJ
Amiens, France, 80054
Sponsors and Collaborators
French Innovative Leukemia Organisation
Mundipharma Pte Ltd.
Investigators
Principal Investigator: Gandhi DAMAJ, MD MS French Innovative Leukemia Organisation
Principal Investigator: Rémy GRESSIN, MD MS French Innovative Leukemia Organisation
Principal Investigator: THierry LAMY, PD MS French Innovative Leukemia Organisation
Principal Investigator: Olivier TOURNILHAC, PD MS French Innovative Leukemia Organisation
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: French Innovative Leukemia Organisation
ClinicalTrials.gov Identifier: NCT00959686     History of Changes
Other Study ID Numbers: "BENTLY"
First Submitted: August 14, 2009
First Posted: August 17, 2009
Last Update Posted: February 12, 2013
Last Verified: June 2011

Keywords provided by French Innovative Leukemia Organisation:
Bendamustine refractory or relapsed T-cell lymphoma.

Additional relevant MeSH terms:
Lymphoma
Lymphoma, T-Cell
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin
Bendamustine Hydrochloride
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents